Evaxion Biotech A/S
NASDAQ Capital MarketTotal Valuation
Evaxion Biotech A/S carries a market capitalization of 24.26M, placing it among publicly traded companies globally. Its enterprise value stands at 1.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 24.26M |
| Enterprise Value | 1.29B |
Share Statistics
Evaxion Biotech A/S currently has 417.01M shares outstanding.
| Shares Outstanding | 417.01M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 3.14, and the price-to-book ratio stands at 135.63.
| PE Ratio | N/A |
| PS Ratio | 3.14 |
| PB Ratio | 135.63 |
| P/TBV Ratio | 135.63 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 171.63 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 3,076.05 |
Financial Position
Evaxion Biotech A/S maintains a current ratio of 5.06, meaning it holds 5.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 74.55, indicating elevated leverage, while an interest coverage ratio of 33.57 demonstrates strong ability to service its debt obligations.
| Current Ratio | 5.06 |
| Quick Ratio | 5.06 |
| Debt / Equity | 74.55 |
| Debt / EBITDA | -0.82 |
| Interest Coverage | 33.57 |
Financial Efficiency
| Return on Equity (ROE) | -109.89 |
| Return on Assets (ROA) | -41.40 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -941,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Evaxion Biotech A/S's stock has declined approximately -45.83921% over the past 52 weeks. The 50-day moving average sits at 3.14, while the 200-day moving average is 3.58.
| Beta (5Y) | N/A |
| 52-Week Price Change | -45.83921% |
| 50-Day Moving Average | 3.14 |
| 200-Day Moving Average | 3.58 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Evaxion Biotech A/S generated 7.49M in revenue and converted that into -8.66M in net income, yielding earnings per share of -1.14. EBITDA reached -8.69M, while operating income came in at -8.69M.
| Revenue | 7.49M |
| Gross Profit | N/A |
| Operating Income | -8.69M |
| Pretax Income | -9.60M |
| Net Income | -8.66M |
| EBITDA | -8.69M |
| EBIT | -8.69M |
| Earnings Per Share (EPS) | -1.14 |
Balance Sheet
Evaxion Biotech A/S holds 14.00M in cash and equivalents against 7.11M in total debt, resulting in a net debt position of -8.69M. Total book value stands at 9.53M, with working capital of 12.73M providing operational flexibility.
| Cash & Cash Equivalents | 14.00M |
| Total Debt | 7.11M |
| Net Debt | -8.69M |
| Equity (Book Value) | 9.53M |
| Book Value Per Share | 0.02 |
| Working Capital | 12.73M |
Margins
Evaxion Biotech A/S operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -116.04 and net profit margin of -115.56 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -116.04 |
| Pretax Margin | -128.12 |
| Profit Margin | -115.56 |
| EBITDA Margin | -116.04 |
Stock Splits
Evaxion Biotech A/S's most recent stock split took place on January 14, 2025 with a 5:1 split ratio.
| Last Split Date | 1/14/2025 |
| Split Ratio | 5:1 |
Scores
Evaxion Biotech A/S posts an Altman Z-Score of 68.80, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 68.80 |